Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Xiaomi Shares Jump on Europe EV Expansion Plan 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Milei Threatens Falkland Oil Firms With Sanctions 
Add as a preferred source on Google
Illumina Inc. is selling its cancer test developer, Grail, following its series of antitrust conflicts. The company is a known maker of gene-sequencing machines, and on Sunday, Dec. 17, it revealed its decision to divest this unit, which it bought in 2021 for $7.1 billion.
According to The New York Times, Illumina's move to divest its Grail unit came two days after the company recently lost in a court battle. It made an appeal, but the federal court largely sided with the Federal Trade Commission when it upheld the antitrust regulator's ruling that Illumina must sell its Grail on antitrust grounds.
Obstruction in Europe
It was reported that Illumina's deal for Grail was also not cleared in Europe, and it has, in fact, faced a roadblock there, too. In September last year, the EU said it would block the acquisition. The company publicly admitted that it had been unsuccessful with its appeals for the Grail deal, and this has led to the decision to divest the start-up.
At any rate, the company's troubles started when it went ahead and purchased the cancer test developer despite the complaint from the U.S. FTC. The commission argued that the buyout would reduce innovation in the American market as well as increase prices.
Execution of Illumina's GRAIL's Sale
The biotechnology company, headquartered in San Diego, California, said that its sale of GRAIL is set to be executed via a third-party or capital markets transaction that is in line with the European Commission's (EU) divestiture order. Illumina aims to finalize the terms of the deal by the end of the second quarter of 2024.
"We are committed to an expeditious divestiture of GRAIL in a manner that allows its technology to continue benefitting patients," Illumina's chief executive officer, Jacob Thaysen, said in a press release. "The management team and I continue to focus on our core business and supporting our customers. I am confident in Illumina's opportunities and our long-term success."
Photo by: Illumina Press Release
